SLC5A2 and type 2 diabetes mellitus: A large clinical trial using dapagliflozin, a SGLT2 inhibitor, found that treatment with dapagliflozin of T2DM patients who had or were at risk for atherosclerotic cardiovascular disease, did not result in a higher or lower rate of cardiovascular events than placebo, but did result in a lower rate of cardiovascular death or hospitalization for HF [11].